Clinical oncology最新文献

{"title":"Efficacy and safety of neoadjuvant Docetaxel, Carboplatin, Trastuzumab, Pertuzumab in patients with HER2-positive early breast cancer - A retrospective study","authors":"L. Koudsi, C. Hockaday, N. Levitt, M. Tuthill, R. Roux, S. Lord, J. Chiramel","doi":"10.1016/j.clon.2024.103717","DOIUrl":"10.1016/j.clon.2024.103717","url":null,"abstract":"","PeriodicalId":10403,"journal":{"name":"Clinical oncology","volume":"38 ","pages":"Article 103717"},"PeriodicalIF":3.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143429027","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neoadjuvant chemotherapy for early breast cancer in young patients: real-world outcomes","authors":"S.R. Javed, S. Mathur, K. DeSouza, A. Konstantis, D. Ottaviani, F. Raja, R. Roylance, T. Walsh, E. Papadimitraki","doi":"10.1016/j.clon.2024.103714","DOIUrl":"10.1016/j.clon.2024.103714","url":null,"abstract":"","PeriodicalId":10403,"journal":{"name":"Clinical oncology","volume":"38 ","pages":"Article 103714"},"PeriodicalIF":3.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143429147","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Single centre experience of neo-adjuvant chemotherapy for HER2 positive early breast cancer and impact of chemotherapy regimen on pathological complete response (pCR)","authors":"M. Joseph, A. Guppy, S. Sutherland, C. Westbury, W. Ng, D. Miles","doi":"10.1016/j.clon.2024.103707","DOIUrl":"10.1016/j.clon.2024.103707","url":null,"abstract":"","PeriodicalId":10403,"journal":{"name":"Clinical oncology","volume":"38 ","pages":"Article 103707"},"PeriodicalIF":3.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143429414","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Alpelisib in advanced breast cancer – a real world report of toxicity and efficacy, a multi-centre analysis","authors":"L. Morrison , D. Banon , I. Gill , N. Cunningham , A. Dua , A. Ballesteros , P.L. Marti , P. Galera , M. Alvarez-Maldonado , A. Iglesias , E. Carrillo , N.C. Turner , M. Parton , S. Johnston , E. Kipps , A.F.C. Okines","doi":"10.1016/j.clon.2024.103708","DOIUrl":"10.1016/j.clon.2024.103708","url":null,"abstract":"","PeriodicalId":10403,"journal":{"name":"Clinical oncology","volume":"38 ","pages":"Article 103708"},"PeriodicalIF":3.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143429298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A retrospective audit of adherence to the IMPORT-HIGH recommendations on clip placement to facilitate breast boost radiotherapy","authors":"L. Alizadeh, A. Mitchell, C. Kane, E. Halliday, S. Needleman","doi":"10.1016/j.clon.2024.103710","DOIUrl":"10.1016/j.clon.2024.103710","url":null,"abstract":"","PeriodicalId":10403,"journal":{"name":"Clinical oncology","volume":"38 ","pages":"Article 103710"},"PeriodicalIF":3.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143429346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Under-representation for Female Pelvis Cancers in Commercial Auto-segmentation Solutions and Open-source Imaging Datasets","authors":"M. Thor ,&nbsp;V. Williams ,&nbsp;C. Hajj ,&nbsp;L. Cervino ,&nbsp;H. Veeraraghavan ,&nbsp;S. Elguindi ,&nbsp;N. Tyagi ,&nbsp;A. Shukla-Dave ,&nbsp;J.M. Moran","doi":"10.1016/j.clon.2024.10.003","DOIUrl":"10.1016/j.clon.2024.10.003","url":null,"abstract":"<div><h3>Aim</h3><div>Artificial intelligence (AI) based auto-segmentation aids radiation therapy (RT) workflows and is being adopted in clinical environments facilitated by the increased availability of commercial solutions for organs at risk (OARs). In addition, open-source imaging datasets support training for new auto-segmentation algorithms. Here, we studied if the female and male anatomies are equally represented among these solutions.</div></div><div><h3>Materials and Methods</h3><div>Inquiries were sent to eight vendors regarding their clinically available OAR auto-segmentation solutions for each gender. The Cancer Imaging Archive (TCIA) was also screened for publicly available imaging datasets specific to the female and the male anatomy.</div></div><div><h3>Results</h3><div>All vendors provided AI based auto-segmentation solutions for the male pelvis and female breasts, while 5/8 vendors provided solutions for the female pelvis. The female breast and the female pelvis solutions were released at a median of 0.6 years and 2.3 years, respectively, after the release of the male pelvis solutions. Among 27 TCIA datasets identified, 15 involved the female anatomy (breast: 10; pelvis: 5) and 12 involved the male pelvis but no female-specific dataset included OAR segmentations, while three male pelvis datasets included OARs (ejaculatory duct, neurovascular bundle, penile bulb and verumontanum).</div></div><div><h3>Conclusion</h3><div>Commercial AI auto-segmentation solutions and open-source imaging datasets include considerably more solutions and OAR segmentations for male cancer over female cancer sites. This gender disparity is likely to propagate throughout the RT pipeline.</div></div>","PeriodicalId":10403,"journal":{"name":"Clinical oncology","volume":"38 ","pages":"Article 103651"},"PeriodicalIF":3.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143001273","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is exercise an important consideration in metastatic breast cancer?","authors":"A. Kuciejewska,&nbsp;C. Lai,&nbsp;M. Kitson,&nbsp;C. McDaid,&nbsp;M. Chody,&nbsp;N. Chopra","doi":"10.1016/j.clon.2024.103718","DOIUrl":"10.1016/j.clon.2024.103718","url":null,"abstract":"","PeriodicalId":10403,"journal":{"name":"Clinical oncology","volume":"38 ","pages":"Article 103718"},"PeriodicalIF":3.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143429190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Systematic Review of Deep Inspiration Breath Hold and Free Breathing in Proton Beam Therapy Plans for Breast Cancer Radiotherapy","authors":"F. Wilson ,&nbsp;P. Gupta ,&nbsp;H. Halvorsen ,&nbsp;C. Anandadas ,&nbsp;D. Lines ,&nbsp;M. Aznar","doi":"10.1016/j.clon.2025.103782","DOIUrl":"10.1016/j.clon.2025.103782","url":null,"abstract":"<div><h3>Aims</h3><div>To conduct a systematic review of breast cancer radiotherapy studies reporting a comparison of proton beam therapy (PBT) in deep inspiration breath hold (DIBH) and in free breathing (FB).</div></div><div><h3>Methods and materials</h3><div>Studies comparing DIBH and FB proton beam therapy plans, in the same patient, published between 2015 and 2023 were included. Doses to organs at risk were compared between DIBH and FB plans.</div></div><div><h3>Results</h3><div>Nine papers were identified for inclusion, reporting on 97 patients in total. All plans were for left-sided treatment. Average weighted mean heart dose was 0.31 Gy for DIBH and 0.48 Gy for FB. Average weighted mean left lung dose was 5.27 Gy for DIBH and 4.80 Gy for FB. Average weighted mean near maximum/maximum left anterior descending artery dose was 6.49 Gy for DIBH and 8.74 Gy for FB.</div></div><div><h3>Conclusion</h3><div>Based on the current literature, it does not appear that DIBH offers a marked dosimetric benefit to most breast cancer patients treated with PBT. However, the benefits of combining PBT and DIBH for individual breast RT patients cannot be excluded.</div></div>","PeriodicalId":10403,"journal":{"name":"Clinical oncology","volume":"40 ","pages":"Article 103782"},"PeriodicalIF":3.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143474199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"National Oncology Trainee Collaborative for Healthcare Research (NOTCH)–Five Years On","authors":"K. Purshouse ,&nbsp;M. Denholm","doi":"10.1016/j.clon.2025.103777","DOIUrl":"10.1016/j.clon.2025.103777","url":null,"abstract":"","PeriodicalId":10403,"journal":{"name":"Clinical oncology","volume":"40 ","pages":"Article 103777"},"PeriodicalIF":3.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143467249","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative Outcomes and Toxicity in Patients With Esophageal Cancer After Trimodality Therapy With Step-and-Shoot Intensity-Modulated Radiation Therapy Versus Volumetric Modulated Arc Therapy: The MD Anderson Experience","authors":"C.O. Abana ,&nbsp;P.P. Carriere ,&nbsp;P.J. Damen ,&nbsp;P.S.N. van Rossum ,&nbsp;A.K. Yoder ,&nbsp;P.L. Bravo ,&nbsp;X. Wei ,&nbsp;J.M. Pollard-Larkin ,&nbsp;P.L. Nitsch ,&nbsp;M.B. Murphy ,&nbsp;W.L. Hofstetter ,&nbsp;Z. Liao ,&nbsp;S.H. Lin","doi":"10.1016/j.clon.2024.103668","DOIUrl":"10.1016/j.clon.2024.103668","url":null,"abstract":"<div><h3>Aims</h3><div>To evaluate outcomes and toxicity after intensity-modulated radiation therapy given as step-and-shoot (SS) or volumetric modulated arc therapy (VMAT) for patients with locally advanced esophageal cancer treated with trimodality therapy (i.e. neoadjuvant concurrent chemoradiation therapy followed by surgery).</div></div><div><h3>Materials and Methods</h3><div>Patients consecutively treated with trimodality therapy including IMRT in 2001–2022 (n = 449) were retrospectively reviewed, and 106 pairs of propensity-matched SS and VMAT patients were identified. Survival, recurrence, surgery-related prognostic factors, and chemoradiation-related toxicities were evaluated between groups.</div></div><div><h3>Results</h3><div>Baseline characteristics were balanced between both groups except for body mass index, history of other cancer, clinical disease stage, and use of induction chemotherapy. Median follow-up time was 40 months. Relative to SS, VMAT led to higher 3-year overall survival (OS; <em>P</em> = 0.028, hazard ratio [HR] 0.645, 95% confidence interval [CI] 0.436–0.954) but not progression-free, locoregional recurrence-free, or distant metastasis-free survival. No predictor of excellent OS by SS versus VMAT was identified in multivariable analyses. However, VMAT was associated with reduced odds of postoperative cardiac complications (<em>P</em> &lt; 0.001, odds ratio [OR] 0.296, 95% CI 0.148–0.591), pulmonary complications (<em>P</em> = 0.048, OR 0.539, 95% CI 0.292–0.994), pathologic partial response or worse (≥10% viable cells; <em>P</em> = 0.003, OR 0.418, 95% CI 0.235–0.743), and positive/close margins (<em>P</em> = 0.023, OR 0.346, 95% CI 0.138–0.867) relative to SS. VMAT was also associated with reduced rates of chemoradiation therapy-related weight loss (33.0% versus 79.2%, <em>P</em> &lt; 0.001), fatigue (40.6% versus 68.9%, <em>P</em> &lt; 0.001), nausea (31.1% versus 58.5%, <em>P</em> &lt; 0.001) and cardiac toxicity (0% versus 6.6%, <em>P</em> = 0.007) than SS.</div></div><div><h3>Conclusion</h3><div>Based on this single institution, retrospective study with a 40-month median follow-up, VMAT utilization in trimodality treatment for locally advanced esophageal cancer appears to be associated with improved OS and rates of concurrent chemoradiation therapy-related toxicity and reduced initial 12-month postoperative complications relative to SS IMRT. Multi-institutional prospective trials addressing the limitations of this study and with longer follow-ups are warranted to validate these findings.</div></div>","PeriodicalId":10403,"journal":{"name":"Clinical oncology","volume":"38 ","pages":"Article 103668"},"PeriodicalIF":3.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142871594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}